Roche Invests US$750m in Oregon Manufacturing Expansion

Just days after Roche announced it had “raised the final beam” to complete its new US$2bn manufacturing facility in Holly Springs, North Carolina, the Swiss firm also announced it will invest US$750m to double the size of its existing manufacturing facility in Hillsboro, Oregon. 

Genentech, a US subsidiary of Roche, will operate both manufacturing facilities as the Swiss pharma giant builds out its US footprint.

Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. It employs over 112,000 people worldwide, generating roughly CHF62 billion (US$77.5bn) in annual revenue. 

Its current US presence includes 13 manufacturing sites, 15 research and development facilities and approximately 25,000 employees across 24 locations in eight states.

Commenting on the expansion, Ashley Magargee, CEO of Genentech, says, “We are proud to make this significant new investment in Hillsboro, building on nearly two decades of Genentech manufacturing in Oregon. 

“By adding end-to-end filling capabilities, this expansion deepens our commitment to manufacturing in the US and gives us the flexibility to support a growing pipeline.”

A critical manufacturing hub

Since opening in 2006, Hillsboro has grown into a cornerstone of Genentech's US manufacturing network, producing medicines across therapeutic areas including oncology, immunology and neurology.

The facility will introduce device-filling capability to the site, further strengthening domestic production and helping build a more resilient, self-sufficient US pharmaceutical supply chain. 

With established infrastructure, proven manufacturing capabilities and a skilled local workforce already in place, Hillsboro is well-positioned for the upcoming expansion — building on nearly two decades of collaboration with state and community partners in the region.

Commitment to US Manufacturing

Expansion to the Hillsboro facility, as well as the Holly Springs site where investment swelled from an initial US$700m to US$2bn, fits into Roche’s wider multi-billion-dollar commitment to US manufacturing.

In April 2026, Roche announced it would invest US$50bn in developing manufacturing infrastructure in the US over the next five years.

Thomas Schinecker, CEO of Roche Group, speaking at the time of the announcement, said that the “investments underscore our long-standing commitment to research, development and manufacturing in the US.” 

“We are proud of our 110-year legacy in the United States, which has been a key driver for jobs, innovation and the creation of intellectual property in the US…Our investments of US$50bn over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”

A recurring pattern

Roche's US investment is part of a much larger wave of reshoring in the US pharmaceutical industry, partly driven in response to US President Donald Trump's threats of tariffs on medicines manufactured overseas.

Novartis has pledged US$23bn to build or expand ten US facilities, while Johnson & Johnson has committed US$55bn to domestic manufacturing, including three new sites. Eli Lilly, meanwhile, is amidst a US$27bn investment spree that includes four additional plants.

Bristol Myers Squibb (BMS) has also deepened its commitment to US biopharmaceutical manufacturing, announcing a $2.3bn "multi-modal manufacturing campus" in Houston, Texas – a milestone step within its broader US$40bn, five-year plan to invest in US research and development, technology and domestic manufacturing.

Discussing BMS' latest move, Christopher Boerner, Board Chair and CEO of BMS, says, "This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation."

"As part of our $40bn commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life."